{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:34:28Z","timestamp":1793237668943,"version":"4.5.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Clinical trials have demonstrated that rituximab improves overall survival in non-Hodgkin lymphoma (NHL), except in mantle cell lymphoma (MCL). We used Surveillance Epidemiology and End Results (SEER)\u2013Medicare data to compare survival in older MCL patients who began chemotherapy with or without rituximab within 180 days of diagnosis. Patients were followed from diagnosis (January 1999 to December 2005) until death or the end of observation (December 2007). Medicare administrative and claims data were used to identify the date and cause of death and the immunochemotherapy regimen. Of 638 patients, the mean age at diagnosis was 75 years, 75% had stage III\/IV disease, 67% had extranodal involvement, and 64% received rituximab. The average length of first-line treatment was 21 weeks, with no difference between the 2 groups (P = .76). Median survival was 27 months for chemotherapy alone, compared with 37 months for chemotherapy plus rituximab (P &lt; .001). In multivariate analysis of 2-year survival, rituximab plus chemotherapy was associated with lower all-cause (hazard ratio [HR] 0.58; 95% confidence interval [CI] 0.41-0.82; P &lt; .01), and cancer-specific (HR 0.56; 95% CI 0.37-0.84; P &lt; .01) mortality. Results were similar when using the entire observation period, propensity score analysis, and limiting chemotherapy to CHOP\/CHOP-like. We conclude that first-line chemotherapy including rituximab is associated with significantly improved survival in older patients diagnosed with MCL.<\/jats:p>","DOI":"10.1182\/blood-2011-04-348367","type":"journal-article","created":{"date-parts":[[2011,8,27]],"date-time":"2011-08-27T01:25:48Z","timestamp":1314408348000},"page":"4808-4816","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":78,"title":["Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma"],"prefix":"10.1182","volume":"118","author":[{"given":"Robert","family":"Griffiths","sequence":"first","affiliation":[{"name":"Outcomes Insights Inc, Westlake Village, CA;"},{"name":"Johns Hopkins University School of Medicine, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Mikhael","sequence":"additional","affiliation":[{"name":"Mayo Clinic Arizona, Scottsdale, AZ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Gleeson","sequence":"additional","affiliation":[{"name":"Outcomes Insights Inc, Westlake Village, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Danese","sequence":"additional","affiliation":[{"name":"Outcomes Insights Inc, Westlake Village, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen, Campus Grosshadern, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111811020956700_B1","first-page":"542","article-title":"Current treatment standards and emerging strategies in mantle cell lymphoma.","author":"European MCL Network","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"2019111811020956700_B2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma.","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111811020956700_B3","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma.","volume":"70","author":"Fern\u00e0ndez","year":"2010","journal-title":"Cancer Res"},{"key":"2019111811020956700_B4","article-title":"Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net).","author":"Hermine"},{"key":"2019111811020956700_B5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111811020956700_B6","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111811020956700_B7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomized controlled trial by the MabThera International Trial (MInT) Group.","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"12","key":"2019111811020956700_B8","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"2019111811020956700_B9","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"15","key":"2019111811020956700_B10","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group hematology and oncology study.","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111811020956700_B11","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111811020956700_B12","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"2019111811020956700_B13","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomised, open-label, phase 3 trial.","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"2019111811020956700_B14","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111811020956700_B15","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"2019111811020956700_B16","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"2019111811020956700_B17","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.584.584","article-title":"Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell lymphoma (MCL) [abstract].","volume":"104","author":"Herold","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2019111811020956700_B18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced mantle cell lymphoma.","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111811020956700_B19","unstructured":"National Cancer Institute\n          Surveillance, epidemiology, and end results. Data set and software.\n          Accessed January 17, 2011\n          Available from http:\/\/seer.cancer.gov\/seerstat\/"},{"key":"2019111811020956700_B20","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma.","volume":"329","author":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"key":"2019111811020956700_B21","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index.","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"2019111811020956700_B22","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"2019111811020956700_B23","first-page":"IV","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"2019111811020956700_B24","unstructured":"National Cancer Institute\n          About the SEER Program\n          Accessed August 27, 2010\n          Available from: http:\/\/seer.cancer.gov\/about\/"},{"key":"2019111811020956700_B25","unstructured":"National Cancer Institute\n          SEER-Medicare: How the SEER & Medicare Data are Linked\n          Accessed August 27, 2010\n          Available from: http:\/\/healthservices.cancer.gov\/seermedicare\/overview\/linked.html"},{"key":"2019111811020956700_B26","unstructured":"North American Association of Central Cancer Registries\n          Guidelines for ICD-O-3 Implementation\n          Accessed February 24, 2011\n          Available from: www.facs.org\/cancer\/coc\/naaccr.pdf"},{"key":"2019111811020956700_B27","first-page":"IV","article-title":"Utility of the SEER-Medicare data to identify chemotherapy use.","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"2019111811020956700_B28","unstructured":"National Cancer Institute\n          Procedure Codes for SEER-Medicare Analysis\n          Accessed December 7, 2010\n          Available from: http:\/\/healthservices.cancer.gov\/seermedicare\/considerations\/procedure_codes.html"},{"key":"2019111811020956700_B29","volume-title":"HCPCS","author":"Practice Management Information Corporation","year":"2005"},{"key":"2019111811020956700_B30","unstructured":"Fritz\n              A\n            \n            \n              Ries\n              L\n            \n          \n          SEER Program Code Manual\n          Accessed October 5, 2010\n          3rd ed\n          Available from: http:\/\/seer.cancer.gov\/manuals\/codeman.pdf"},{"key":"2019111811020956700_B31","unstructured":"Young\n              JL\n              Jr\n            \n            \n              Roffers\n              SD\n            \n            \n              Ries\n              LAG\n            \n            \n              Fritz\n              AG\n            \n          \n          SEER Summary Staging Manual - 2000 Codes and Coding Instructions. (National Institutes of Health publication number 01-4969).\n          Accessed January 4, 2011\n          Available from: http:\/\/seer.cancer.gov\/tools\/ssm\/intro.pdf"},{"key":"2019111811020956700_B32","volume-title":"ICD-9-CM","author":"Practice Management Information Corporation","year":"2005","edition":"6th ed"},{"issue":"13","key":"2019111811020956700_B33","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1182\/blood-2010-08-301929","article-title":"An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia.","volume":"117","author":"Danese","year":"2011","journal-title":"Blood"},{"key":"2019111811020956700_B34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group.","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"13","key":"2019111811020956700_B35","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2009.25.4052","article-title":"Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer.","volume":"28","author":"Davidoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111811020956700_B36","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data.","volume":"53","author":"Klabunde","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"2019111811020956700_B37","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.annepidem.2007.03.011","article-title":"A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.","volume":"17","author":"Klabunde","year":"2007","journal-title":"Ann Epidemiol"},{"key":"2019111811020956700_B38","unstructured":"National Cancer Institute\n          SEER-medicare: calculation of comorbidity weights\n          Accessed August 27, 2010\n          Available from: http:\/\/healthservices.cancer.gov\/seermedicare\/program\/comorbidity.html"},{"key":"2019111811020956700_B39","unstructured":"National Cancer Institute\n          Overview of the SEER Program\n          Accessed August 27, 2010\n          Available from: http:\/\/healthservices.cancer.gov\/seermedicare\/program\/charlson.comorbidity.macro.txt"},{"key":"2019111811020956700_B40","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2019111811020956700_B41","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"2019111811020956700_B42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0895-4356(94)90006-X","article-title":"A comparison of administrative versus clinical data: coronary artery bypass surgery as an example. Ischemic Heart Disease Patient Outcomes Research Team.","volume":"47","author":"Romano","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"2019111811020956700_B43","unstructured":"National Comprehensive Cancer Network\n          NCCN Clinical Practice Guidelines in Oncology Non-Hodgkin's Lymphomas V. 1.2010\n          Accessed January 4, 2011\n          Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp"},{"key":"2019111811020956700_B44","article-title":"CMS 301: Using SEER\/Medicare Data for Research.","volume-title":"ResDAC","author":"ResDAC. Research Data Assistance Center","year":"2008"},{"key":"2019111811020956700_B45","doi-asserted-by":"crossref","first-page":"IV","DOI":"10.1097\/00005650-200208001-00011","article-title":"Identifying cancer relapse using SEER-Medicare data.","volume":"40","author":"Earle","year":"2002","journal-title":"Med Care"},{"key":"2019111811020956700_B46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1524-4733.2007.00226.x","article-title":"Ten-year survival and cost following breast cancer recurrence: estimates from SEER-Medicare data.","volume":"11","author":"Stokes","year":"2008","journal-title":"Value in Health"},{"key":"2019111811020956700_B47","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7326\/0003-4819-127-8_Part_2-199710151-00064","article-title":"Estimating causal effects from large data sets using propensity scores.","volume":"127","author":"Rubin","year":"1997","journal-title":"Ann Intern Med"},{"issue":"12","key":"2019111811020956700_B48","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ajh.21878","article-title":"Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy.","volume":"85","author":"Griffiths","year":"2010","journal-title":"Am J Hematol"},{"key":"2019111811020956700_B49","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/1471-2407-10-625","article-title":"Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL).","volume":"10","author":"Griffiths","year":"2010","journal-title":"BMC Cancer"},{"key":"2019111811020956700_B50","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/cncr.23452","article-title":"Limits of observational data in determining outcomes from cancer therapy.","volume":"112","author":"Giordano","year":"2008","journal-title":"Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/18\/4808\/1464055\/zh804411004808.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/18\/4808\/1464055\/zh804411004808.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T11:22:24Z","timestamp":1574076144000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/18\/4808\/29350\/Addition-of-rituximab-to-chemotherapy-alone-as"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,3]]},"references-count":50,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2011,11,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-04-348367","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,3]]}}}